Herbimycin A, a benzoquinonoid
ansamycin antibiotic, reduces intracellular phosphorylation by some
protein tyrosine kinases and inhibits the proliferation of malignant cells which express high
tyrosine kinase activity.
Herbimycin A inhibited the proliferation of human monoblastic
leukemia U937 cells, but this inhibition was abrogated by the addition of
granulocyte-macrophage colony-stimulating factor (
GM-CSF). On the other hand, a derivative of
herbimycin A,
19-allylaminoherbimycin A, inhibited the proliferation of such cells without interference by the addition of
GM-CSF. Phosphorylation of MAP
kinase and c-myc expression induced by
GM-CSF in U937 cells were inhibited by both
herbimycin A and
19-allylaminoherbimycin A. The time courses of growth inhibition showed that the growth-inhibitory activity of
herbimycin A in U937 cells was initially potent, but gradually decreased in the presence of
GM-CSF.
Thiol compounds,
glutathione (GSH) and
2-mercaptoethanol, abrogated the inhibition of the growth of U937 cells by
herbimycin A, but not by
19-allylaminoherbimycin A, like
GM-CSF. Intracellular GSH content in U937 cells was increased by treatment with
GM-CSF, and decreased with
herbimycin A, but returned to the control level with the addition of
GM-CSF to
herbimycin A. In thin-layer chromatography, after in vitro incubation with
herbimycin A and GSH, nothing could be detected at the position of intact
herbimycin A, while
19-allylaminoherbimycin A was stably detected. These findings suggest that changes in the intracellular concentration of GSH play a role in the abrogation of the inhibition of U937 cell growth by
herbimycin A. In the presence of GSH,
19-allylaminoherbimycin A inhibited the proliferation of U937 cells and
Philadelphia chromosome-positive K562 cells more effectively than
herbimycin A. Since GSH plays a role in detoxicating several anticancer drugs,
19-allylaminoherbimycin A may have therapeutic advantages over
herbimycin A against some types of
leukemia.